Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0082 | 1 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0072 | 0.8643 | 0.8159 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.005 | 0.5433 | 0.2407 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0082 | 1 | 1 |
Brugia malayi | flavodoxin family protein | 0.0031 | 0.2628 | 0.2628 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0082 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0082 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0031 | 0.2628 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.005 | 0.5433 | 0.5 |
Leishmania major | cytochrome P450 reductase, putative | 0.0072 | 0.8643 | 0.8643 |
Trypanosoma cruzi | p450 reductase, putative | 0.0082 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0082 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0031 | 0.2628 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.005 | 0.5433 | 0.5433 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0072 | 0.8643 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0041 | 0.3985 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0082 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0072 | 0.8643 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0082 | 1 | 1 |
Treponema pallidum | flavodoxin | 0.0031 | 0.2628 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.005 | 0.5433 | 0.5433 |
Loa Loa (eye worm) | flavodoxin family protein | 0.0031 | 0.2628 | 0.2628 |
Leishmania major | p450 reductase, putative | 0.0082 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0082 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0082 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0082 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0031 | 0.2628 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0082 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0031 | 0.2628 | 0.5 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0031 | 0.2628 | 0.2628 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0031 | 0.2628 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0041 | 0.3985 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0082 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0082 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 1 | 1 |
Trypanosoma cruzi | NADPH--cytochrome P450 reductase, putative | 0.0031 | 0.2628 | 0.2628 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0031 | 0.2628 | 0.2628 |
Leishmania major | hypothetical protein, conserved | 0.0031 | 0.2628 | 0.2628 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0041 | 0.4076 | 0.0151 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0072 | 0.8643 | 0.8159 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0082 | 1 | 1 |
Trypanosoma brucei | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0031 | 0.2628 | 0.2628 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0082 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0082 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0082 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0082 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0082 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.